Ultragenyx Pharmaceutical Inc. Annual Income Tax Expense (Benefit) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2013 to 2023.
  • Ultragenyx Pharmaceutical Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $303K, a 53.4% decline year-over-year.
  • Ultragenyx Pharmaceutical Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$2.09M, a 590% decline year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.83M, a 132% decline from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Income Tax Expense (Benefit) for 2022 was $5.7M, a 446% increase from 2021.
  • Ultragenyx Pharmaceutical Inc. annual Income Tax Expense (Benefit) for 2021 was $1.04M, a 13.5% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$1.83M -$7.52M -132% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 $5.7M +$4.65M +446% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $1.04M -$163K -13.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 $1.21M -$2.08M -63.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
2019 $3.28M +$2.77M +539% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $514K +$16.7M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-12
2017 -$16.2M -$16.2M -46383% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 $35K +$35K Jan 1, 2016 Dec 31, 2016 10-K 2019-02-20
2015 $0 $0 Jan 1, 2015 Dec 31, 2015 10-K 2016-02-26
2014 $0 $0 Jan 1, 2014 Dec 31, 2014 10-K 2016-02-26
2013 $0 Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.